Literature DB >> 14555913

Association of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies with Vienna classification subtypes of Crohn's disease.

Frank H Klebl1, Frauke Bataille, Claudia R Bertea, Hans Herfarth, Ferdinand Hofstädter, Jürgen Schölmerich, Gerhard Rogler.   

Abstract

BACKGROUND: The Vienna classification of Crohn's disease (CD) subdivides patients according to their age at diagnosis (A), disease location (L), and disease behavior (B). AIM The aim of this study was to test whether perinuclear antineutrophil cytoplasmic antibodies (pANCAs) or anti-Saccharomyces cerevisiae antibodies (ASCAs) correlate to subtypes of CD according to this classification.
METHODS: pANCA, ASCA-immunoglobulin (Ig) A, and ASCA-IgG were detected by indirect immunofluorescence in 120 sera of patients with CD and compared with their Vienna classification.
RESULTS: Patients with diagnosis of CD at an age of 40 years or older (A2) were more frequently pANCA-positive than those whose disease started at a younger age (A1) (19% vs. 5%, p < 0.05). pANCA-positive patients almost exclusively belonged to the nonpenetrating disease groups (B1 and B2); only one patient had penetrating disease (B3) (B3 vs. non-B3: p = 0.02). There was a cluster of pANCA-positive patients within the A1 B2 L3 subgroup (B2: stricturing disease; L3: ileocolonic involvement). Only 7.5% of ASCA-IgA-positive patients presented with CD that was limited to the colon (L2). ASCA-IgA and ASCA-IgG were more frequently found in patients with upper gastrointestinal disease (L4) (ASCA-IgA: 66.7% vs. 31.5% in non-L4, p < 0.05; ASCA-IgG: 44.4% vs. 27.9%, p < 0.05).
CONCLUSION: pANCA and ASCA may be useful in predicting subtypes of CD. They therefore may be helpful in developing subtype-specific disease management strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555913     DOI: 10.1097/00054725-200309000-00003

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  14 in total

Review 1.  Relevance of serologic studies in inflammatory bowel disease.

Authors:  Gwenola Vernier; Boualem Sendid; Daniel Poulain; Jean-Frédéric Colombel
Journal:  Curr Gastroenterol Rep       Date:  2004-12

Review 2.  Immunogenetic phenotypes in inflammatory bowel disease.

Authors:  Marla-C Dubinsky; Kent Taylor; Stephan-R Targan; Jerome-I Rotter
Journal:  World J Gastroenterol       Date:  2006-06-21       Impact factor: 5.742

3.  Diagnostic role and clinical association of ASCA and ANCA in Brazilian patients with inflammatory bowel disease.

Authors:  Renato Mitsunori Nisihara; Wilson Beleski de Carvalho; Shirley Ramos da Rosa Utiyama; Heda Amarante; Márcia Luiza Baptista
Journal:  Dig Dis Sci       Date:  2009-10-14       Impact factor: 3.199

4.  Contribution of immunofluorescence to identification and characterization of antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Authors:  Dorra Bouzid; Samy Haddouk; Ali Amouri; Youssef Ben Hadj Hmida; Nabil Tahri; Hatem Masmoudi
Journal:  Indian J Gastroenterol       Date:  2011-10-11

5.  Analysis of serum antibodies in patients suspected of having inflammatory bowel disease.

Authors:  Troy D Jaskowski; Christine M Litwin; Harry R Hill
Journal:  Clin Vaccine Immunol       Date:  2006-06

6.  Determination of Anti-Anisakis Simplex Antibodies and Relationship with αβ and γδ Lymphocyte Subpopulations in Patients with Crohn's Disease.

Authors:  C Benet-Campos; C Cuéllar; C García-Ballesteros; V Zamora; R Gil-Borrás; I Catalán-Serra; F López-Chuliá; J C Andreu-Ballester
Journal:  Dig Dis Sci       Date:  2017-02-06       Impact factor: 3.199

7.  Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease.

Authors:  Gottfried Novacek; Wolfgang Miehsler; Julia Palkovits; Walter Reinisch; Thomas Waldhör; Stylianos Kapiotis; Alfred Gangl; Harald Vogelsang
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

8.  Is the disease course predictable in inflammatory bowel diseases?

Authors:  Peter Laszlo Lakatos; Lajos S Kiss
Journal:  World J Gastroenterol       Date:  2010-06-07       Impact factor: 5.742

Review 9.  Utility of serological markers in inflammatory bowel diseases: gadget or magic?

Authors:  Maria Papp; Gary L Norman; Istvan Altorjay; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2007-04-14       Impact factor: 5.742

10.  Optimising the diagnostic value of anti-Saccharomyces cerevisiae-antibodies (ASCA) in Crohn's disease.

Authors:  Frank H Klebl; Frauke Bataille; Ferdinand Hofstädter; Hans Herfarth; Jürgen Schölmerich; Gerhard Rogler
Journal:  Int J Colorectal Dis       Date:  2004-01-27       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.